
样式: 排序: IF: - GO 导出 标记为已读
-
Re: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-29
Petra Petranović Ovčariček,Murat Tuncel,Michael C Kreissl,Alfredo Campennì,Bart de Keizer,Désirée Deandreis,Luca Giovanella -
Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [18F]FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-29
Clemens P Spielvogel,Aleksa Lazarevic,Lucia Zisser,David Haberl,Christophoros Eseroglou,Lucian Beer,Marcus Hacker,Raffaella Calabretta -
Five-year follow-up of Estimabl 2 trail: a critical appraisal. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-29
Murat Tuncel,Petra Petranovic Ovcaricek,Luca Giovanella -
Association of PET vascular activity score with Takayasu's arteritis angiographic progression. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-28
Sifan Wu,Bing Wu,Lingying Ma,Mengdi Li,Xianting Sun,Shuhui Zhang,Hongcheng Shi,Lindi JiangOBJECTIVE Arterial wall Fluorodeoxyglucose (FDG) uptake can reflect vascular inflammation in Takayasu's arteritis (TAK); however, its association with vascular prognosis remains unclear. This study assessed the predictive efficacy of the PET vascular activity score (PETVAS) for vascular prognosis and whether FDG uptake in specific arterial territories was associated with angiographic progression in
-
PET imaging of TREM2 in amyloid-beta induced neuroinflammation. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-28
Amelia D Dahlén,Sahar Roshanbin,Ximena Aguilar,Nadja M Bucher,Sara Lopes van den Broek,Dag Sehlin,Stina SyvänenPURPOSE The triggering receptor expressed on myeloid cells 2 (TREM2) has become a promising target for biologics in both monitoring and treating neuroinflammation in Alzheimer's disease (AD). This study aimed to develop and compare bispecific anti-TREM2 antibodies featuring different transferrin receptor (TfR) binders to enhance brain delivery, identifying the most suitable format for in vivo PET imaging
-
Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-27
Chunsheng Wang,Congjie Wang,Jianguo Zhang,Mingjun Ding,Yizhi Ge,Xia HeBACKGROUND Non-small cell lung cancer (NSCLC) is a highly heterogeneous malignancy characterized by altered glucose metabolism. Integration of PET/CT radiomics with glucose metabolism-related genomic signatures could provide a more comprehensive approach for prognosis and treatment guidance. METHODS Radiomics features were extracted from PET/CT images of 156 NSCLC patients from The Cancer Imaging Archive
-
Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-27
Jiajun Ye,Shu Yang,Yu Liu,Zhiyong Quan,Mingru Zhang,Guiyu Li,Zifan Zhu,Jia Wang,Taoqi Ma,Junlin Wang,Zhibo Liu,Jing Wang,Fei KangPURPOSE Fibroblast activation protein (FAP) has emerged as one of the most promising theranostic targets. FT-FAPI, a potential FAP-targeted probe with enhanced tumor-targeting ability using an organotrifluoroborate linker, was verified for the biological effect in cell and animal experiments in previous work. However, the differences in pharmacokinetic profiles, biodistribution and dosimetry of FT-FAPI
-
Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-27
Osama Mahmoud,Lukas Püllen,Lale Umutlu,Tibor Szarvas,Wolfgang P Fendler,Saskia Ting,Henning Reis,Henning Bayer,Ken Herrmann,Boris A Hadaschik,Mulham Al-Nader,Christoph BerlinerPURPOSE The aim of this study was to, evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) in high-risk prostate cancer (PC) compared to [¹⁸F]PSMA / [⁶⁸Ga]Ga- PSMA- and [¹⁸F]FDG- PET/CT as well as multiparametric magnetic resonance imaging (MRI). MATERIALS AND METHODS Ten patients with high-risk PC (PSA > 20 ng/mL, Gleason score > 7, or > T2c)
-
Combined perfusion and metabolic imaging of small cell lung cancer with dual-isotope LAFOV-PET. Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-27
Nasir Gözlügöl,Hasan Sari,Tereza Losmanová,Ali Afshar-Oromieh,Axel Rominger,Federico Caobelli -
Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Cong Shi, Di Sun, Yu-Qing Sun, Xin Zhang, Sheng-Yan Liu, Qi-Jun Li, Yi-Jin Pan, Wen-Ting Guo, Ying-Qiang Zhang, Xiao-Na Jin, Yu Liu, Yan-Song LinPurpose To date, the survival benefits of multiple radioactive iodine therapies (RAIT) in RAI-avid pulmonary micrometastatic differentiated thyroid cancer (DTC) remain debatable. This study aimed to compare the progression-free survival (PFS) benefits between those received only once RAIT (o-RAIT) and multiple RAITs (m-RAIT) in such patients. Methods Patients with RAI-avid pulmonary micrometastatic
-
PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Ilanah J. Pruis, Vera van Dis, Sybren L. N. Maas, Rutger K. Balvers, Thierry P. P. van den Bosch, Marcel Segbers, Sophie E. M. Veldhuijzen van ZantenPurpose Prostate-specific membrane antigen (PSMA) is a potential target for radioligand therapy (RLT) in neuro-oncology. This study investigates the direct relation between [68Ga]Ga-PSMA-11 uptake on PET and PSMA expression in the tumour micro-environment of high-grade glioma (HGG) and brain metastasis (BM). Methods Twelve patients with HGG (glioblastoma n = 6, oligodendroglioma n = 1), or BM (lung-
-
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Yueling Deng, Xiao Zhang, Fan Hu, Xiaoli LanPurpose This study aimed to evaluate the predictive value of 18F-FDG PET/CT for pathological complete response (pCR) after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer (NSCLC) and develop a quantitative pCR prediction model. We compared the model's performance with RECIST 1.1 and PERCIST. Method A retrospective review was conducted on patients with resectable NSCLC who received
-
Texture analysis and metabolic parameters of 18F-FDG PET/CT to predict primary tumour response and prognosis of paediatric soft tissue sarcomas Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Ayşenur Sinem Kartal, Mehmet Oğuz Kartal, Nadide Başak Gülleroğlu, Neriman Sarı, İnci Ergürhan İlhan, Nedim C. M. GülaldıIntroduction We aimed to investigate the value of primary tumour F-18 fluorodeoxyglucose (18F-FDG) parameters and textural features in predicting tumour response to neoadjuvant chemoradiotherapy (neo-CRT) and prognosis in paediatric patients with soft tissue sarcoma (STS). Materials and methods Twenty-eight paediatric patients with STS who underwent 18F-FDG PET/CT studies before neo-CRT were included
-
Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R Chandekar, Chandan K Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Bhagwant R MittalPurpose Treatment response assessment in grade 1/2 neuroendocrine tumors (NETs) has been a key challenge due to their indolent nature. Here, we propose the novel response evaluation criteria with [68Ga]Ga-somatostatin analogue (SSA)-PET/CT in grade 1/2 NETs (RECIN) following [177Lu]Lu-DOTATATE therapy and evaluate its survival impact vis-à-vis conventional radiographic response assessment. Methods
-
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3) Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Moritz B. Bastian, Benedikt Wörl, Arne Blickle, Caroline Burgard, Tilman Speicher, Mark Bartholomä, Andrea Schaefer-Schuler, Stephan Maus, Samer Ezziddin, Florian RosarPurpose Given the increasing inclusion of ECOG 3 patients in oncology practice, data on this subgroup in the context of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) remain limited. This study evaluates the safety and outcome of PSMA-RLT in metastatic castration-resistant prostate cancer (mCRPC) patients with ECOG performance status 3. Methods In this analysis, a cohort
-
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Xiaorui Chen, Sun Yu, Xinhui Su, Jingsong He, Peipei Wang -
Diffuse uptake in the subcutaneous tissue on 18F-Florbetapir PET/CT Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-26
Zhenchun Xu, Qiaoqiao Shu, Yue Feng, YongZeng Fan, Xiaojiao Xiang -
Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via [68Ga]Ga-FAPI-46 PET/CT imaging Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-24
Dan Ruan, Sien Shi, Weixi Guo, Yizhen Pang, Lingyu Yu, Jiayu Cai, Zhenyu Wu, Hua Wu, Long Sun, Liang Zhao, Haojun ChenPurpose Accurate differentiation of the histologic invasiveness of early-stage lung adenocarcinoma is crucial for determining surgical strategies. This study aimed to investigate the potential of [68Ga]Ga-FAPI-46 PET/CT in assessing the invasiveness of early lung adenocarcinoma presenting as ground-glass nodules (GGNs) and identifying imaging features with strong predictive potential. Methods This
-
First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-24
Guillaume P. Nicolas, Manuel Alejandre Lafont, Lisa McDougall, Felix Kaul, Alin Chirindel, Wolfgang Weber, Angela Llmazares, Anass Johayem, Markus Baier, Nicole Schubert, Francesco De Rose, Leila Jaafar-Thiel, Andreas Bauman, Melpomeni Fani, Damian Wild -
Detecting early cardiomyopathy in transthyretin variant carriers: reappraising the diagnostic value of Perugini grade 1 radiotracer uptake on bone scintigraphy Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-23
H. S. A. Tingen, M. Berends, A. Tubben, P. van der Meer, R. H. J. A. Slart, J. Bijzet, P. A. van der Zwaag, C. Kimmich, C. Knackstedt, F. L. H. Muntinghe, E. J. Houwerzijl, B. P. C. Hazenberg, H. L. A. NienhuisPurpose To determine whether TTRv carriers with Perugini grade 1 cardiac radiotracer uptake on [99mTc]Tc- hydroxydiphosphonate bone scintigraphy have or develop ATTR-CM. Methods This retrospective observational study was conducted at the Groningen Amyloidosis Centre of Expertise between April 2012 and June 2023. TTRv carriers with Perugini grade 1 uptake on bone scintigraphy were followed until to
-
The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-22
Marnix G. E. H. Lam, Etienne Garin, Kirk D. Fowers, Armeen Mahvash, Siddharth A. Padia, Riad SalemPurpose To investigate relationships between treatment week, relative to Ytrrium-90 (90Y) glass microsphere calibration (i.e., specific activity and particle density), and outcomes for hepatocellular carcinoma (HCC) or colorectal cancer liver metastasis (mCRC). Methods Multinational, multicenter study TARGET (retrospective; n = 209 HCC patients) was combined with EPOCH (phase III trial; n = 428 mCRC
-
Preclinical evaluation of [211At]At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-20
Jiajia Zhang, Shanshan Qin, Xuhao Huang, Erina Hilmayanti, Fan Hu, Xiaohui Luan, Tianzhen Ye, Feize Li, Yuanyou Yang, Ning Liu, Kazuya Kabayama, Koichi Fukase, Fei YuPurpose The aim of this study is to overcome the challenges of poor tumor penetration and systemic toxicity in targeted alpha therapy (TAT) while also evaluating its immunomodulatory effects to enhance antitumor immune responses in melanoma treatment. Methods This study developed a 211At-labeled single-domain antibody agent ([211At]At-AuNP-ABDMPL16) targeting PD-L1, a protein overexpressed in melanoma
-
Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-21
Anna Julie Kjøl Høyvik, Monika Kvassheim, Li-Wei Ma, Elisabeth Wiig, Tiril Hillestad, Mona-Elisabeth Revheim, Rugile Liukaityte, Øyvind Bruland, Asta JuzenieneBackground Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [212Pb]Pb-AB001 could offer enhanced treatment by delivering
-
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-21
Matteo Bagnalasta, Stefania Mazzaglia, Maria Chiara De Nile, Chiara Romanò, Giovanna Pitoni, Alice Phillips, Gaetano Amato, Carlo Spreafico, Carlo Morosi, Tommaso Cascella, Alfonso Marchianò, Marianna Maspero, Valentina Bellia, Gianluca Aliberti, Alessandra Alessi, Vincenzo Mazzaferro, Marco Maccauro, Carlo ChiesaPurpose 90Y glass microspheres have a shelf life of 12 days from the calibration date, allowing flexible administration after a variable decay interval. For a fixed intended activity, a longer interval results in a higher number of administered microspheres per GBq and in a lower activity per sphere as. This study aimed to demonstrate that, for a fixed Tumour Absorbed Dose (TAD), Tumour Control Probability
-
The brain-white adipose tissue axis may play a crucial role in diabetes mellitus: a metabolic network analysis using total-body PET/CT imaging Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-20
Lubing Sun, Yaping Wu, Junpeng Yang, Junting Liang, Panlong Li, Xuan Yu, Nan Meng, Tao Sun, Meiyun Wang, Chuanliang ChenPurpose This study aims to construct an individualized glucose metabolism network using total-body 18F-FDG PET imaging, which provides a comprehensive view of glucose metabolism across various organs, to explore the role of inter-organ interactions in Diabetes Mellitus (DM). Methods In this study, we constructed covariance metabolic networks using static total-body PET images, normalized by lean body
-
Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-19
Amir Karimzadeh, Kimberley Hansen, Stefan Hein, Bernhard Haller, Matthias M. Heck, Robert Tauber, Calogero D`Alessandria, Matthias Eiber, Isabel RauscherPurpose This retrospective analysis evaluated the prognostic value of baseline 18F-flotufolastat-PET bone tumor metrics for severe hematologic toxicity in metastatic castration-resistant prostate cancer (mCRPC) patients treated with [177Lu]Lu-PSMA-I&T. Methods Data from 182 mCRPC patients with baseline 18F-flotufolastat-PET scans and complete hematologic profiles were analyzed. Bone lesions were semiautomatically
-
First clinical investigation to predict lymphovascular and/or perineural invasion in gastric cancer using 18F-FAPI-42 PET/CT parameters Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-19
Lilan Fu, Fei Xie, Penghui Sun, Ye Dong, Kemin Zhou, Li Jiang, Ruihe Wu, Yanjiang Han, Hubing Wu, Ganghua Tang, Wenlan ZhouObjective This study was conducted to explore the predictive value of PET parameters derived from 18F-FAPI-42 PET/CT in assessing lymphovascular and/or perineural invasion (LVI/PNI) in gastric cancer (GC) patients. Methods 72 GC patients who underwent 18F-FAPI-42 PET/CT prior to surgical resection were included. Clinicopathological factors and PET parameters were collected and analyzed in LVI/PNI-negative
-
Functional intra thoracic kidney due to Bochdalek hernia detected in [18F]FDG PET/CT performed for lung cancer staging Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-19
Soler Claude, Datry Vincent, Pegard Clothilde, Mathieu Gauthé -
Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-19
Zekai Li, Janneke W. de Boer, Tom van Meerten, Anne G. H. Niezink, Walter Noordzij, Adriaan A. Lammertsma, Charalampos Tsoumpas, Adrienne H. Brouwers -
Initial [18F]FDG PET/CT study for survival evaluation of lung transplantation patients with interstitial lung disease Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-14
Lin Chen, Jing Wang, Chentao Jin, Congcong Yu, Yan Zhong, Xiaofeng Dou, Xiaohui Zhang, Piaopiao Zhang, Juan Chen, Jingyu Chen, Mei Tian, Hong Zhang, Rui ZhouPurpose This study aimed to investigate the role of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in survival prediction of interstitial lung diseases (ILD) patients undergoing lung transplantation (LTx). Methods Eighty-three patients with ILD who underwent LTx were retrospectively included in this study, among whom 43 received unilateral LTx and 40 received
-
Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-14
Rajiv Ranjit Nair, Aira Sarkar, Pooja Hariharan, Kathleen L. Gabrielson, Tony Wu, Chang Liu, Anjali Sharma, Wathsala Liyanage, Zaver M. Bhujwalla, Marie-France Penet Vidaver, Rangaramanujam M. Kannan, Stavroula SofouPurpose The poor prognosis of glioblastoma is mostly due to the relatively low tumor vascular permeability to therapeutics, the tumor’s vicinity to the brain, that limits treatment aggressiveness, and/or drug resistance. Methods In this study, the efficacy of systemically injected actinium-225 dendrimer-radioconjugates was evaluated in an immune-competent orthotopic GL261-C57BL/6 mouse model after
-
Post-COVID-19 lung disease: utility of biochemical and imaging markers in uncovering residual lung inflammation and monitoring anti-inflammatory therapy, a prospective study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-13
Yogita Khandelwal, Manish Ora, Bela Jain, Manish Dixit, Prakash Singh, Ajmal Khan, Alok Nath, Vikas Agarwal, Sanjay GambhirPurpose Post-COVID-19 lung disease (PCLD) is a significant concern following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. PCLD encompasses persistent debilitating respiratory symptoms and radiological changes beyond the acute disease phase. It highlights the ongoing search to identify and manage lingering diseases. This prospective study utilizes F18-Fludeoxyglucose (FDG)
-
Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-13
Ying Cong, Rianne Biemans, Natasja G. Lieuwes, Dennis Suijlen, Philippe Lambin, Ingrid Dijkgraaf, Matthias Bauwens, Ala Yaromina, Ludwig J. DuboisPurpose In this study, we investigated the utility of a novel developed anti-CEACAM5 VHH for cancer diagnosis and its potential of being a targeting-moiety of VHH-drug conjugates for cancer therapy. Methods Anti-CEACAM5 VHH (6B11) affinity and specific cellular binding was confirmed by ELISA, FACS and immunofluorescence in cancer cell lines with varying CEACAM5 expression levels. Intracellular penetration
-
18F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-13
Xilan Yao, Hongrong Wang, Xiao Lei, Jialing Cui, Shuang Yao, Jigang YangPurpose We aimed to evaluate the prognostic value of pre- and post-infusion 18F-FDG PET/CT for B-cell non-Hodgkin lymphoma B-NHL) patients treated with anti-CD19 chimeric antigen receptor T (CAR-T) cells. Methods B-NHL patients who received CAR-T therapy and underwent 18F-FDG PET/CT examination one month before (pre-infusion) and after (M1) CAR-T infusion were collected and regularly followed up. Maximum
-
Directional interactions from non-small cell lung cancer to brain glucose metabolism revealed by total-body PET imaging Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-09
Tianzheng Zhong, Yanhua Duan, Kun Li, Jianfeng Qiu, Zhaoping Cheng, Weizhao LuPurpose Imaging markers for lung-brain interaction and brain metastasis of non-small cell lung cancer (NSCLC) are lacking. This study aimed to explore the effect of NSCLC on brain glucose metabolism using total-body positron emission tomography (PET) imaging. Methods Fifty-six healthy controls (HCs) and 42 NSCLC patients underwent total-body PET imaging. Concentrations of serum tumor markers were obtained
-
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-09
Donglang Jiang, Zhaohui Chu, Yanfei Wu, You Zhang, Yao Liu, Qi Ge, Yue Gu, Zunguo Du, Yuanyuan Cheng, Xiwen Xu, Yuan Huang, Dong Xu, Yihui Guan, Weijun Wei, Fang XiePurpose Gallium-68 (68Ga)-labeled [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) holds great promise as a non-invasive technique for visualizing the expression of trophoblast cell-surface antigen 2 (TROP2). This approach may potentially assist in making clinical decisions regarding TROP2-targeted therapies. The present study aims to evaluate the utility of [68Ga]Ga-NOTA-T4 PET/CT
-
To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-09
Luigi Asmundo, Felipe Furtado, Francis Delaney, Mojtahed Amirkasra, Azadeh Hajati, Abdar Esfahani Shadi, Avinash Kambadakone, Lawrence Blaszkowsky, Jeffrey Clark, David Ryan, Onofrio Antonio CatalanoPurpose The role of hepatobiliary contrast-enhanced imaging in the evaluation of liver malignancies in FDG-PET/MR remains underexplored. The aim of this study was to assess the diagnostic performance of stand-alone FDG-PET, non-contrast-enhanced (NCE) PET/MR, and contrast-enhanced (CE) PET/MR with and without hepatobiliary phase (HBP). Methods This prospective, single-center diagnostic accuracy study
-
Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Pascalle Mossel, Giordana Salvi de Souza, Antoon T. M. Willemsen, Gilles N. Stormezand, Nicola A. Colabufo, Jun Toyohara, Hendrikus H. Boersma, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Anna L. Bartels, Gert LuurtsemaIntroduction P-glycoprotein (P-gp) or multidrug-resistance protein is one of the most extensively studied efflux transporters at the blood-brain barrier (BBB). Changes in P-gp function are associated with several neurodegenerative and psychiatric diseases, including Alzheimer’s disease, Parkinson’s disease and schizophrenia and with the bioavailability of several pharmaceuticals in the brain, causing
-
Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Carolin Brinkmann, Richard P. Baum, Tom StargardtPurpose To evaluate the cost-effectiveness of 177Lu-PSMA-617 radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer (mCRPC) in Germany by comparing (I) PRLT plus standard-of-care (SoC) versus SoC alone as third-line treatment and (II) PRLT versus second-line cabazitaxel chemotherapy. Methods Cohort state-transition models were developed with (I) four health states (treatment
-
HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Yuan Gao, Lei Yin, Xiaojiang Duan, Zijian Fu, Qian Liu, Jinzhi Chen, Ling Xin, Xiaojuan Zhu, Hongyu Xiang, Ling Xu, Jingming Ye, Meng LiuPurpose Human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with 18F-FDG PET/CT. Methods In this prospective
-
Noninvasive diagnosis and classification of kidney transplantation rejection by 18F-FAPI-04 PET/CT Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Sulin Luo, Mimi Xu, Rongfang Shen, Meifang Wang, Qinyun Wu, Tianlu Zhang, Zhenpeng Jin, Pengpeng Yan, Luying Guo, Jingyi Zhou, Qin Zhou, Huiping Wang, Kui Zhao, Xinhui Su, Rending WangPurpose Rejection, especially chronic rejection is a key factor influencing the prognosis of kidney transplantation patients. While 18F-fibroblast activation protein inhibitor (FAPI)-04 PET/CT has been widely utilized for diagnosing various diseases, its diagnostic efficacy in kidney transplant rejection remains unexplored. Methods In this study, 24 kidney transplant recipients were prospectively enrolled
-
Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Yanfei Wu, Hao Wang, Yue Gu, You Zhang, Guanglei Li, Yuan Huang, Min Cao, Xiaofeng Chen, Yihui Guan, Dong Xu, Weijun Wei, Fang XieBackground Immunotherapy based on programmed cell death protein receptor 1 and its ligand (PD-1/PD-L1) has become an important method for treating non-small cell lung cancer (NSCLC). Peptide-based and nanobody-based PET tracers offer potential advantages in PD-L1 detection, yet their comparative tumor uptake and biodistribution remain unclear. This study aimed to evaluate and compare [68Ga]Ga-DOTA-WL12
-
The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Jian Xu, Haisong Chen, Lixuan Chen, Tiancheng Li, Heng Lin, Shuying Bian, Qi Lin, Yuandi Zhuang, Yingnan Xue, Yunjun Yang, Xinhui Su, Fei YaoPurpose This study aimed to develop a predictive model that integrates parameters derived from preoperative multiparametric magnetic resonance imaging (mpMRI) and [18F]PSMA-1007 PET/CT for reliably predicting pathological upgrading from systematic biopsy (SB) to radical prostatectomy (RP) specimens. Methods We ultimately retrospectively analyzed 163 patients with biopsy-confirmed localized prostate
-
[18F]FDG PET/CT imaging in a patient with diffuse skeletal muscle metastasis of thyroid carcinoma Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-08
Yanwei Wang, Jialin Xiang, Zhaohui Zhu -
Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-06
James Nagarajah, Hyun Kim, Luke Nordquist, Vikas Prasad, Nathaniel Scott, Daniel Stevens, Benjamin Fongenie, Joseph OsbornePurpose To evaluate tumour and normal organ dosimetry of PSMA-targeted RLT 177Lu-rhPSMA-10.1. Methods PSMA-positive mCRPC patients experiencing disease progression following standard-of-care treatment were enrolled and underwent ≤ 3 cycles of 5.55 or 7.40 GBq 177Lu-rhPSMA-10.1 at 6-week intervals. Multi-bed SPECT/CT was conducted 3-, 24-, 48-, and 168-hours post-administration to calculate tumour and
-
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-06
Yuan Gao, Zijian Fu, Xiaojuan Zhu, Hongfeng Li, Lei Yin, Caixia Wu, Jinzhi Chen, Yulong Chen, Li Liang, Jingming Ye, Ling Xu, Meng LiuPurpose The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs. Methods Consecutive 207 breast cancer patients (211 primary lesions)
-
Evidence for brain glial activity in chronic migraine patients: a [11C] PBR28 PET/MR study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-06
Yan Chang, Xiwan Zhang, Shaobo Xiao, Jiajin Liu, Yuan Wang, Jingbin Song, Huaping Fu, Yungang Li, Hui Su, Huijie Yi, Wenjie Su, Nan Gao, JinJing Zhao, Ruimin Wang, Ruozhuo LiuPurpose Although neuroinflammation may play a key role in the pathology of migraine and its progression to chronic migraine (CM), its specific involvement-particularly the role of microglia- remains unclear. We investigated whether neuroinflammation is involved in the pathophysiology of CM and whether pro-inflammatory signals are associated with its clinical features. Methods Nineteen individuals with
-
[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-06
Sophie Carina Kunte, Astrid Delker, Adrien Holzgreve, Mathias J. Zacherl, Maximilian Scheifele, Jozefina Casuscelli, Franz Josef Gildehaus, Marcus Unterrainer, Harun Ilhan, Rudolf A. Werner, Lena M. UnterrainerPurpose Radioligand therapy (RLT) targeting PSMA (prostate-specific membrane antigen) has transformed the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, bone marrow depletion remains a common side effect, particularly in patients with extensive bone metastases or prior myelotoxic therapies. This study evaluated [99mTc]Tc-antigranulocyte scintigraphy to assess bone marrow
-
Total-body 11C-PIB PET/CT imaging of systemic amyloidosis: inter-organ connectivity in cardiac amyloidosis for prognostic insights Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-05
Zhihui Hong, Song Xue, Josef Yu, Raffaella Calabretta, David Haberl, Zewen Jiang, Stefan Grünert, Dietrich Beitzke, Andreas Kammerlander, Marcus Hacker, Xiang LiBackground Amyloidosis is a systemic disorder characterized by amyloid fibril deposition in multiple organs, including the heart, brain, liver, kidneys, and lungs, leading to organ dysfunction and affecting survival. In cardiac amyloidosis (CA), where the heart is primarily affected, the broader impact on other organs, particularly the brain, is not fully understood. This study aimed to assess the
-
Comparison of 18F-DPA714 PET/MRI and 18F-FDG PET/CT in patients with autoimmune encephalitis: a cross-sectional study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-03
Huanyu Meng, Xiaoyu Chen, Lu He, Hangxing Chunyu, Qinming Zhou, Jin Wang, Qian Qu, Wangxi Hai, Yu Zhang, Biao Li, Sheng Chen, Min ZhangBackground and aim The positive detection rate of MRI in autoimmune encephalitis (AIE) patients is low, often failing to make a rapid and accurate localization diagnosis. Both 18F-DPA714 and 18F-FDG PET imaging techniques have shown their advantages in the diagnosis of AIE. Therefore, the aim of this study was to conduct a head-to-head comparison of the diagnostic value between 18F-DPA714 and 18F-FDG
-
PET imaging utilization and trends in Germany: a comprehensive survey Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-03
Adrien Holzgreve, Dirk Hellwig, Henryk Barthel, Ambros J. Beer, Carsten Kobe, Constantin Lapa, Matthias Miederer, Sarah Schwarzenböck, Robert Seifert, Andrei Todica, Ken Herrmann, Frank M. Bengel, Michael Schäfers, Detlef Moka, Markus Luster, Wolfgang P. FendlerIntroduction PET imaging is a key diagnostic procedure in clinical routine worldwide. While public figures on PET volume are available in many countries, until now these numbers were not publicly known for Germany. Methods On behalf of the PET committee of the German Society of Nuclear Medicine, we conducted a comprehensive survey among PET centers in Germany to collect data on PET imaging, including
-
[18F]flutemetamol uptake in the colon of a memory clinic population and its association with brain amyloidosis and the gut microbiota profile: an exploratory study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-02
Giulia Quattrini, Elena Gatti, Débora Elisa Peretti, Marco Aiello, Claire Chevalier, Aurelien Lathuiliere, Rahel Park, Michela Pievani, Marco Salvatore, Max Scheffler, Annamaria Cattaneo, Giovanni B. Frisoni, Valentina Garibotto, Moira MarizzoniPurpose Some Alzheimer’s disease (AD) patients report gastro-intestinal symptoms and present alterations in the gut microbiota (GM) composition. Elevated colonic amyloid immunoreactivity has been shown in patients and animal models. We evaluated the colonic uptake of the amyloid positron emission tomography (PET) imaging agent [18F]flutemetamol (FMM) in a memory clinic population and investigated its
-
Should end-to-end deep learning replace handcrafted radiomics? Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-02
Irène Buvat,Joyita Dutta,Abhinav K Jha,Eliot Siegel,Fereshteh Yousefirizi,Arman Rahmim,Tyler Bradshaw -
Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI-46 for evaluation of structural damage and inflammation in axial spondyloarthritis: a prospective study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-01
Yangchun Chen, Lingyu Yu, Shiju Chen, Wen Liu, Haiwei Han, Yizhen Pang, Qingyan Lin, Yan Li, Liying Chen, Jiayu Cai, Liang Zhao, Long Sun, Guixiu Shi, Haojun Chen, Yuan LiuObjective Axial spondyloarthritis (axSpA) is characterized by active inflammation and structural damage. To date, there is no imaging tool can alone visualize all those changes well. PET/CT imaging with gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) provide extra ability for CT in detecting active inflammation in addition to its advantage in assessing structural damage. This
-
Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-01
Hongzhe Zhang, Qingqing Pan, Silu Liu, Jie Feng, Miao Yu, Naishi Li, Qiang Xu, Xianlin Han, Fang Li, Yaping LuoPurpose Accurate preoperative localization is imperative for the treatment of insulinomas. Glucagon-like peptide-1 receptor (GLP-1R) imaging has demonstrated remarkable efficacy in localization of insulinomas. The aim of this study was to assess the diagnostic performance of GLP-1R PET/CT with 68Ga-exendin-4 in localization of insulinoma, and to provide evidence for clinical practice from a real-world
-
Accelerated Chronic Lymphocytic Leukaemia with aggressive disease progression and Richter’s transformation: a potential novel diagnostic application of [68Ga]Ga-PentixaFor PET/CT demonstrating high in-vivo CXCR- 4 expression with discordant [18F]F-FDG-PET/CT finding Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-01
Meghna Choudhury, Rahul V. Parghane, Sandip Basu -
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard” Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-05-01
Christian Kuehnel -
Clinical value of CXCR4-targeted PET-CT in primary aldosteronism: a systematic review and meta-analysis Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-04-30
Ranbie Tang, Jingguang Pu, Zhanwen HuangPurpose Primary aldosteronism (PA), a common cause of secondary hypertension, requires precise localization and subtype differentiation for appropriate management. C-X-C chemokine receptor 4 (CXCR4) targeted PET-CT emerges as a promising non-invasive modality for evaluating PA. This study aims to assess its performance in three key areas: lateralizing aldosterone secretion, differentiating PA subtypes
-
A novel molecular imaging technique using [68Ga]Ga-mDesmo PET-CT for localizing tumors in Cushing’s disease Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-04-30
Rama Walia, Ananda Mohan Chakraborty, Somit Pandey, Nivedita Rana, Rajender Kumar, Chirag Ahuja, Harmandeep Singh, Sivashanmugam Dhandapani, Sushant Kumar Sahoo, Rajesh Chhabra, Apinderpreet Singh, Sanjay Kumar Bhadada, B. R. Mittal, Debajyoti Chatterjee, Ashley Grossman, Jaya ShuklaIntroduction Localizing the source of adrenocorticotropic hormone (ACTH) in patients with ACTH-dependent Cushing’s syndrome (CS) poses significant challenges. There is a pressing need for novel imaging modalities that provide both anatomical delineation and functional confirmation of corticotropinomas. Methods This study utilized a modified form of desmopressin (mDesmo), an agonist of the V1b receptor
-
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007 Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2025-04-30
Caroline Burgard, Madita Frei, Arne Blickle, Philipp E. Hartrampf, Manuela A. Hoffmann, Mathias Schreckenberger, Hans-Peter Schmid, Lena Unterrainer, Julian Rogasch, Markus Galler, Samer Ezziddin, Florian RosarBackground Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels